Regulus (RGLS) ProspectsJust wondering what thoughts were after recent news from Regulus (see Dr. KSS 2/3/16 post).
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Notice: Undefined variable: karmaOutput in /home/sgumdev/public_html/wp-content/themes/sgum_2016/functions.php on line 3288
rgls hasn’t looked good since last march. stay out.
Team,
$RGLS well it sure has performed well since I acquired shares. In fact it is my only current Biotech holding in the green at +35%. Certainly still much closer to its 52 week low ($5.14) than its 52 week high ($21.22) with an average target price of $31. Like many emerging Biotechs it could also be a possible buy out candidate. Earnings on Monday but earnings are far less important with emerging Biotechs.
V/R
Tom
I am thinking along those same lines. Attractive price, possible highly successful drug making 52-week even less meaningful, possible buy-out candidate. Cash burn rate?